Nuveen’s BridgeBio Pharma BBIO Stock Holding History

Nuveen’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,155	Closed	-$20	–	3215
2023 Q2	$20	Buy	+1,155	New	+$17.4K	﹤0.01%	3198

Other funds holding BBIO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen's BBIO Position: Q1 2026 in Review

Nuveen increased its BridgeBio Pharma (BBIO) stake by 14% in Q1 2026, buying an estimated $4.92M and bringing the position to 562,696 shares worth $41.8M. The position accounts for 0.01% of the portfolio, ranked #732.

Nuveen first reported a position in BBIO in Q3 2019 and has held it in 27 quarters since. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Nuveen held 562,696 shares of BridgeBio Pharma worth $41.8M as of Q1 2026.
Nuveen bought 67,911 BridgeBio Pharma shares in Q1 2026, an estimated $4.92M.
BridgeBio Pharma made up 0.01% of Nuveen's portfolio in Q1 2026, its #732 holding.
Nuveen first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 27 quarters since.
458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.